NCT01344018 2023-04-24
STRASS
European Organisation for Research and Treatment of Cancer - EORTC
Phase NA Completed
Clinical Trials
12 trialsNCT00354835 2023-01-31
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Completed
NCT00346164 2022-04-28
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT00354744 2020-01-29
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Children's Oncology Group
Phase 3 Completed
NCT00589121 2019-06-12
Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00112489 2018-09-25
Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
GOG Foundation
Phase 2 Completed
NCT00379145 2017-12-12
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
Phase 2 Completed
NCT00068367 2017-11-06
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
SWOG Cancer Research Network
Phase 2 Completed
NCT00066365 2015-03-30
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Children's Oncology Group
Phase 2 Completed
NCT00470275 2014-10-20
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Children's Oncology Group
Phase 2 Completed
NCT00072280 2014-09-30
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
Children's Oncology Group
Phase 2 Terminated
NCT00742924 2014-07-04
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Children's Oncology Group
Phase 1 Completed